BioCentury | Nov 4, 2020
Product Development

Data Byte: BMS TYK2 inhibitor could set bar for oral efficacy in psoriasis

With Bristol Myers’ TYK2 inhibitor beating blockbuster psoriasis drug Otezla in a Phase III trial, the next question is how the oral therapy’s efficacy stacks up to that of injectable mAbs.  Bristol Myers Squibb Co....
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Aug 5, 2020
Product Development

I-SPY COVID brings new set of targets to master protocols for acute respiratory distress

While most master protocols for COVID-19 have converged on an overlapping set of experimental therapies, the COVID R&D Alliance’s adaptive trial is kicking off with five therapeutic targets largely untouched in the indication. Three members...
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

Among four new biotech listings Friday, three priced upsized IPOs that each delivered more than $200 million in proceeds, but none of the quartet enjoyed the kind of satisfying first-day pop other biotechs have had...
BioCentury | Jul 3, 2020
Finance

On heels of $100M raise, Annexon joins burgeoning IPO queue

Two days after raising $100 million in a series D round heavy with crossover investors, Annexon has filed to go public on NASDAQ. The filing adds to a burgeoning IPO queue and caps another busy...
BioCentury | May 28, 2020
Product Development

May 27 Quick Takes: EC approves Zeposia in RRMS; plus Dupixent approved in children, La Jolla, Shionogi, Alnylam and Bold

EC approves Zeposia ozanimod for relapsing-remitting MS The European Commission approved Zeposia ozanimod from Bristol Myers Squibb Co. (NYSE:BMY) to treat relapsing-remitting multiple sclerosis (RRMS). FDA approved the S1P receptor modulator in March for relapsing...
BioCentury | Apr 10, 2020
Product Development

COVID-19 roundup: New immune targets to address pandemic; plus updates from CanSino, Arcturus, Fujifilm and more

At least three new treatments for the inflammatory complications of SARS-CoV-2 infection, each with a target new to clinical COVID-19 countermeasures, have or will soon enter human studies. Movement on other fronts against the pandemic...
BioCentury | Mar 27, 2020
Product Development

March 26 Quick Takes: Pear’s digital therapeutic approved for insomnia; plus Medimetriks-Otsuka, Merck KGaA, Jazz, Roche, EpiVax

FDA approves Pear’s cognitive behavioral insomnia therapy FDA approved Somryst from Pear Therapeutics Inc. to treat chronic insomnia. The prescription digital therapeutic is the first to be approved via simultaneous review under the standard 510(k)...
BioCentury | Mar 19, 2020
Emerging Company Profile

OncoOne: targeting oxidized MIF for solid tumors

A trio of Shire veterans launched OncoOne on Wednesday with a €13 million series A round and a batch of biologics against oxidized MIF, a highly selective tumor antigen that was abandoned by the pharma...
BioCentury | Mar 13, 2020
Finance

Cratering market spoils Imara’s NASDAQ debut

Imara managed to make its public debut Thursday after raising $75.2 million in an IPO; however, the hemoglobinopathy company’s shares were immediately swept up in Thursday’s market turmoil. Imara Inc. (NASDAQ:IMRA) slipped $1 to $15...
Items per page:
1 - 10 of 1209